৳ 250/unit
Pack: ৳ 2,500
৳ 250/unit
Pack: ৳ 2,500
At a glance
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used for the treatment of advanced prostate cancer. It competitively binds to pituitary GnRH receptors, reducing LH and FSH release, and consequently testosterone.
Indications
- Advanced prostate cancer
Pharmacology
Relugolix is a non-peptide small molecule GnRH receptor antagonist that competitively binds to pituitary GnRH receptors. It reduces LH and FSH release, decreasing testosterone production, which slows prostate cancer growth.
Dosage
Adult Dose (Oral):
- Loading dose: 360 mg on the first day
- Maintenance dose: 120 mg once daily (at approximately the same time each day)
- Can be taken with or without food
- Missed dose: If >12 hours, skip and resume with next scheduled dose
- If treatment interrupted for >7 days, restart with loading dose
Side effects
Common Side Effects (≥10%):
- Hot flushes
- Increased glucose
- Increased triglycerides
- Musculoskeletal pain
- Decreased hemoglobin
- Increased ALT
- Fatigue
- Increased AST
- Constipation
- Diarrhea
Use in pregnancy
Use in Pregnancy: Safety not established; can cause fetal harm; do not use.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
- QT/QTc interval may be prolonged (androgen deprivation therapy)
- Embryo-fetal toxicity: Can cause fetal harm; males with female partners of reproductive potential should use effective contraception
- Do not use during pregnancy
Overdose effects
No specific experience in management of overdose; consult your doctor if taken in excess.
Storage conditions
Store in a cool and dry place, protected from light and moisture; keep out of reach of children.